NASDAQ · VMD

Viemed Healthcare, Inc.. Common

$12.11 +$0.34 (+2.89%) 1D Market open

Key Metrics

$451.22M
Market cap
30.30×
P/E · TTM
$286.57M
Revenue · TTM
$14.89M
Net income
EPS · TTM $0.36
Dividend yield
Free cash flow $25.92M
Beta · 1Y 0.51
EBITDA · TTM $51.72M
Gross margin 57.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 7
    The stock moved +8.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 7
  • May 6
    The stock moved -12.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$451.22M
Enterprise value$450.67M
Shares outstanding38.3M
52-wk range$5.93 – $12.61
Avg volume · 20D164.8K
Net cash $557.00K
Book value / share$3.46
IndustryServices-Misc Health & Allied Services, Nec
ExchangeNASDAQ
About Viemed Healthcare, Inc.. Common
IPO dateJan 3, 2018
Employees1382

Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E30.30
P/S1.57
P/FCF17.41
EV/EBITDA8.71
EV/Sales1.57
Graham №$5.27

Profitability

Gross 57.6%
Operating 7.7%
Net 5.2%
FCF 9.0%
ROE / ROIC 10.8% · 10.7%

Financial Health

Current ratio1.22
Quick ratio1.10
Debt / equity0.06
Debt / EBITDA 0.18Low leverage
Net cash $557.00K
Working capital$9.11M

Cash Flow · TTM

Operating CF $57.13M
Capex −$31.21M
Free cash flow $25.92M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

7.9
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$5.27 vs $12.12
Trades 2.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings